Virtus ETF Advisers LLC Has $74,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Virtus ETF Advisers LLC lowered its stake in Scholar Rock Holding Co. (NASDAQ:SRRK) by 82.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,707 shares of the company’s stock after selling 8,064 shares during the period. Virtus ETF Advisers LLC’s holdings in Scholar Rock were worth $74,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. FMR LLC grew its stake in Scholar Rock by 33.7% in the 4th quarter. FMR LLC now owns 13,635,261 shares of the company’s stock valued at $589,316,000 after buying an additional 3,439,215 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Scholar Rock by 7.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company’s stock worth $401,231,000 after purchasing an additional 629,315 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Scholar Rock by 17.6% during the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company’s stock worth $205,013,000 after purchasing an additional 708,817 shares in the last quarter. Marshall Wace LLP grew its position in shares of Scholar Rock by 1,283.7% during the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company’s stock worth $127,301,000 after purchasing an additional 2,732,546 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Scholar Rock during the 4th quarter worth approximately $86,043,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Wedbush restated an “outperform” rating and set a $50.00 target price on shares of Scholar Rock in a research report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Scholar Rock presently has an average rating of “Buy” and a consensus price target of $42.67.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, CFO Edward H. Myles sold 142,292 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the sale, the chief financial officer now owns 111,345 shares of the company’s stock, valued at approximately $3,966,108.90. This trade represents a 56.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mo Qatanani sold 68,510 shares of the firm’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total value of $2,562,274.00. Following the completion of the sale, the insider now directly owns 111,084 shares in the company, valued at approximately $4,154,541.60. This represents a 38.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 250,231 shares of company stock valued at $9,056,086. 13.30% of the stock is currently owned by corporate insiders.

Scholar Rock Stock Performance

NASDAQ SRRK opened at $31.67 on Tuesday. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of -13.48 and a beta of 0.56. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm’s 50 day simple moving average is $32.64 and its 200 day simple moving average is $35.76.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.